Cargando…

Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study

Duvelisib (IPI‐145) is an oral dual inhibitor of phosphoinositide‐3‐kinase (PI3K)‐δ and ‐γ in clinical development for the treatment of hematologic malignancies, including indolent non‐Hodgkin lymphoma (iNHL). In a Phase 1, open‐label study to determine the maximum tolerated dose (MTD), pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flinn, Ian W., Patel, Manish, Oki, Yasuhiro, Horwitz, Steven, Foss, Francine F., Allen, Kerstin, Douglas, Mark, Stern, Howard, Sweeney, Jennifer, Kharidia, Jahnavi, Kelly, Patrick, Kelly, Virginia M., Kahl, Brad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220789/ https://www.ncbi.nlm.nih.gov/pubmed/30033575 http://dx.doi.org/10.1002/ajh.25228

Ejemplares similares

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)
por: Vorobyev, V., et al.
Publicado: (2022)

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Kawada, Jun‐ichi, et al.
Publicado: (2018)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib
por: Shah, Ankit, et al.
Publicado: (2021)

Factors Impacting Treatment Decision Making in Older Adults With Indolent Non-Hodgkin Lymphoma
por: Trevino, Kelly, et al.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
por: Rodrigues, Daniel A., et al.
Publicado: (2019)

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS
por: Zinzani, P. L., et al.
Publicado: (2022)

P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
por: Mehta-Shah, Neha, et al.
Publicado: (2023)

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials
por: Wang, Zhongwang, et al.
Publicado: (2023)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

Development and validation of an UPLC-ESI-MS/MS method for quantification of duvelisib in plasma: application to pharmacokinetic study in rats
por: Darwish, Ibrahim A., et al.
Publicado: (2023)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
por: Kharidia, Jahnavi, et al.
Publicado: (2021)

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
por: Davids, Matthew S., et al.
Publicado: (2020)

A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia
por: Gadi, Deepti, et al.
Publicado: (2022)

Effect of Duvelisib, a Selective PI3K Inhibitor on Seizure Activity in Pentylenetetrazole-Induced Convulsions Animal Model
por: Abdolrahmani, Mahnaz, et al.
Publicado: (2023)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
por: Willard, Patrick, et al.
Publicado: (2021)

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
por: Oki, Yasuhiro, et al.
Publicado: (2017)

Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway
por: Li, Xiaohe, et al.
Publicado: (2023)

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
por: Goldsmith, Scott R, et al.
Publicado: (2023)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
por: Minson, Adrian, et al.
Publicado: (2022)

Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma
por: Hidman, Josefin, et al.
Publicado: (2023)

A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
por: Sayed, Ahmed Y, et al.
Publicado: (2021)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

Case Reports of Tectal Plate Gliomas Showing Indolent Course
por: Kim, Jae-Woong, et al.
Publicado: (2020)

Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report
por: Hughes, Caren L, et al.
Publicado: (2014)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas
por: Artemaki, Pinelopi I., et al.
Publicado: (2021)

Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis
por: Hadi, I., et al.
Publicado: (2021)

Vδ2+ and α/Δ T cells show divergent trajectories during human aging
por: Tan, Crystal Tze Ying, et al.
Publicado: (2016)

Mitotic errors, aneuploidy and micronuclei in Hodgkin lymphoma pathogenesis
por: Krem, Maxwell M., et al.
Publicado: (2013)

Pd-Catalyzed Aerobic Oxidative Heck Cross-Coupling for the Straightforward Construction of Indole δ-Lactams
por: Zhang, Jing, et al.
Publicado: (2019)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a309o4meht3b3rr0a5p4vamk58